0

Close
 
Upcoming Allied Market Research
2023
Long-acting Insulin Market

Long-acting insulin market by Product Type (Raditional Human Insulin, Basal or Long-acting Insulin, Bolus or Fast-acting Insulin, Insulin Combinations, and Biosimilar Insulin): Global Opportunity Analysis and Industry Forecast, 2021-2030 Market

LS : Pharmaceuticals
Report Code: A13356
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Long-acting Insulin Market

Request Now !

Insulin moves sugar (glucose) from blood to cells for energy or capacity. On the off chance that you take insulin, you may require some at supper time to assist with bringing down your glucose after you eat. In any case, even between suppers, you need insulin in modest quantities to assist with keeping glucose stable.

Here, long-acting insulin comes into play. Long-acting insulin can assist an individual with balancing out glucose levels for the duration of the day utilizing just a couple of shots. It imitates the low-level progression of insulin that a solid pancreas discharges among dinners and overnight. It attempts to set up a solid pattern glucose level. This implies that when food enters the body, blood glucose will increment from a lower and more customary point, making it simpler to oversee. Long-acting insulin would not fill its need in pill structure as the stomach would separate it during assimilation. All things being equal, individuals with diabetes ought to infuse insulin into the greasy tissue under the skin. From here, it step by step moves into the circulatory system. Each sort of long-acting insulin has its own proposed portion. These differ contingent upon the sort of diabetes and any set of experiences of insulin use. There can be some side effects after the usage of insulin such as dizziness, chills, blurred vision, weakness, headache, and fainting. Other conceivable results of insulin infusions incorporate agony, redness, or growing of the skin at the infusion site.

COVID-19 Impact Analysis

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the global long acting insulin market.

Top Impacting Factors

  • Approximately, 100 million individuals all throughout the planet need insulin, including every one individuals experiencing type-1 diabetes, and 10-25% of individuals with type-2 diabetes that spurs an enormous interest for the long acting insulin.
  • In spite of the fact that insulin has been utilized in the treatment of diabetes across the world for more than 90 years, the greater part of the populace needing insulin today, actually, cannot manage or get to it which goes about as a restriction for the market .
  • Individuals with type-1 diabetes need insulin treatment, and the treatment centers around overseeing glucose levels with insulin, diet, and way of life, to forestall entanglements another factor that lifts up the market for long acting insulin.
  • The R&D in the insulin sections are rising year-on-year, as scientists are attempting to draw out the best particle for patients' utilization, checking out greatest results, and expanding their effectiveness making a colossal market for the insulin.
  • The expanding commonness of heftiness and diabetes across the world is probably going to increase extensive interest for insulin, which may drive the worldwide market for insulin therapeutics.

Key Market Trends

  • North America dominates the worldwide human insulin market, particularly the U.S., attributable to the high pervasiveness of diabetes in the district as a result of a stationary way of life.
  •  The expense factor is the significant worry in the U.S., where practically 50% of the insulin incomes for the producers are from the actual nation.
  • The U.S. represents the most noteworthy deals of the long-acting insulin across the world. Most of diabetic medication fabricating organizations think about the nation as a basic market for working on generally worldwide deals.
  •  Lantus is the most managed basal insulin across the world, representing a prevailing offer in the U.S. market.
  • The customary North American human insulin drugs market is relied upon to develop during the gauge time frame, due to its monetary moderateness by patients. Humulin holds the most noteworthy portion of the overall industry, trailed by Novolin.
  •  There are no conventional contenders for the customary North American human insulin drugs market in the U.S.
  • In less tough administrative conditions, like India, China, Mexico, and Peru, a few biosimilar insulin as of now exist at lower costs.

Key Benefits of the Report

  • This study presents the analytical depiction of the long acting insulin industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the long acting insulin market share.
  • The current market is quantitatively analyzed to highlight the long acting insulin market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.

Questions Answered in the Long Acting Insulin market Report

  • Which are the leading players active in the long acting insulin market?
  • How is each segment of the market expected to grow during the forecast period?
  • What are the adoption trends for the long acting insulin market in emerging economies and established economies across the world?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps?
  • What are the impacts of COVID-19 in the industry?
  • What is long acting insulin?
  • What is the long acting insulin market prediction in the future?
  • What are the current trends and predicted trends?

 Long-acting insulin market by Product Type Report Highlights

Aspects Details
By Product Type
  • Raditional Human Insulin
  • Basal or Long-acting Insulin
  • Bolus or Fast-acting Insulin
  •  Insulin Combinations
  • Biosimilar Insulin
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players Novo Nordisk, Boehringer Ingelheim, Pfizer Inc., Julphar, SEDICO, Exir, Eli Lilly, Biocon Limited, Wockhardt, Sanofi Avantis
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: LONG-ACTING INSULIN MARKET, BY PRODUCT TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product Type

    • 4.2. Raditional Human Insulin

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Basal Or Long-acting Insulin

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Bolus Or Fast-acting Insulin

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5.  Insulin Combinations

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Biosimilar Insulin

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

  • CHAPTER 5: LONG-ACTING INSULIN MARKET, BY REGION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Region

    • 5.2. North America

      • 5.2.1. Key Market Trends and Opportunities

      • 5.2.2. Market Size and Forecast, By Product Type

      • 5.2.3. Market Size and Forecast, By Country

      • 5.2.4. U.S. Long-acting Insulin Market

        • 5.2.4.1. Market Size and Forecast, By Product Type

      • 5.2.5. Canada Long-acting Insulin Market

        • 5.2.5.1. Market Size and Forecast, By Product Type

      • 5.2.6. Mexico Long-acting Insulin Market

        • 5.2.6.1. Market Size and Forecast, By Product Type

    • 5.3. Europe

      • 5.3.1. Key Market Trends and Opportunities

      • 5.3.2. Market Size and Forecast, By Product Type

      • 5.3.3. Market Size and Forecast, By Country

      • 5.3.4. France Long-acting Insulin Market

        • 5.3.4.1. Market Size and Forecast, By Product Type

      • 5.3.5. Germany Long-acting Insulin Market

        • 5.3.5.1. Market Size and Forecast, By Product Type

      • 5.3.6. Italy Long-acting Insulin Market

        • 5.3.6.1. Market Size and Forecast, By Product Type

      • 5.3.7. Spain Long-acting Insulin Market

        • 5.3.7.1. Market Size and Forecast, By Product Type

      • 5.3.8. UK Long-acting Insulin Market

        • 5.3.8.1. Market Size and Forecast, By Product Type

      • 5.3.9. Russia Long-acting Insulin Market

        • 5.3.9.1. Market Size and Forecast, By Product Type

      • 5.3.10. Rest Of Europe Long-acting Insulin Market

        • 5.3.10.1. Market Size and Forecast, By Product Type

    • 5.4. Asia-Pacific

      • 5.4.1. Key Market Trends and Opportunities

      • 5.4.2. Market Size and Forecast, By Product Type

      • 5.4.3. Market Size and Forecast, By Country

      • 5.4.4. China Long-acting Insulin Market

        • 5.4.4.1. Market Size and Forecast, By Product Type

      • 5.4.5. Japan Long-acting Insulin Market

        • 5.4.5.1. Market Size and Forecast, By Product Type

      • 5.4.6. India Long-acting Insulin Market

        • 5.4.6.1. Market Size and Forecast, By Product Type

      • 5.4.7. South Korea Long-acting Insulin Market

        • 5.4.7.1. Market Size and Forecast, By Product Type

      • 5.4.8. Australia Long-acting Insulin Market

        • 5.4.8.1. Market Size and Forecast, By Product Type

      • 5.4.9. Thailand Long-acting Insulin Market

        • 5.4.9.1. Market Size and Forecast, By Product Type

      • 5.4.10. Malaysia Long-acting Insulin Market

        • 5.4.10.1. Market Size and Forecast, By Product Type

      • 5.4.11. Indonesia Long-acting Insulin Market

        • 5.4.11.1. Market Size and Forecast, By Product Type

      • 5.4.12. Rest of Asia Pacific Long-acting Insulin Market

        • 5.4.12.1. Market Size and Forecast, By Product Type

    • 5.5. LAMEA

      • 5.5.1. Key Market Trends and Opportunities

      • 5.5.2. Market Size and Forecast, By Product Type

      • 5.5.3. Market Size and Forecast, By Country

      • 5.5.4. Brazil Long-acting Insulin Market

        • 5.5.4.1. Market Size and Forecast, By Product Type

      • 5.5.5. South Africa Long-acting Insulin Market

        • 5.5.5.1. Market Size and Forecast, By Product Type

      • 5.5.6. Saudi Arabia Long-acting Insulin Market

        • 5.5.6.1. Market Size and Forecast, By Product Type

      • 5.5.7. UAE Long-acting Insulin Market

        • 5.5.7.1. Market Size and Forecast, By Product Type

      • 5.5.8. Argentina Long-acting Insulin Market

        • 5.5.8.1. Market Size and Forecast, By Product Type

      • 5.5.9. Rest of LAMEA Long-acting Insulin Market

        • 5.5.9.1. Market Size and Forecast, By Product Type

  • CHAPTER 6: COMPETITIVE LANDSCAPE

    • 6.1. Introduction

    • 6.2. Top Winning Strategies

    • 6.3. Product Mapping Of Top 10 Player

    • 6.4. Competitive Dashboard

    • 6.5. Competitive Heatmap

    • 6.6. Top Player Positioning,2022

  • CHAPTER 7: COMPANY PROFILES

    • 7.1. Novo Nordisk

      • 7.1.1. Company Overview

      • 7.1.2. Key Executives

      • 7.1.3. Company Snapshot

      • 7.1.4. Operating Business Segments

      • 7.1.5. Product Portfolio

      • 7.1.6. Business Performance

      • 7.1.7. Key Strategic Moves and Developments

    • 7.2. Eli Lilly

      • 7.2.1. Company Overview

      • 7.2.2. Key Executives

      • 7.2.3. Company Snapshot

      • 7.2.4. Operating Business Segments

      • 7.2.5. Product Portfolio

      • 7.2.6. Business Performance

      • 7.2.7. Key Strategic Moves and Developments

    • 7.3. Boehringer Ingelheim

      • 7.3.1. Company Overview

      • 7.3.2. Key Executives

      • 7.3.3. Company Snapshot

      • 7.3.4. Operating Business Segments

      • 7.3.5. Product Portfolio

      • 7.3.6. Business Performance

      • 7.3.7. Key Strategic Moves and Developments

    • 7.4. Biocon Limited

      • 7.4.1. Company Overview

      • 7.4.2. Key Executives

      • 7.4.3. Company Snapshot

      • 7.4.4. Operating Business Segments

      • 7.4.5. Product Portfolio

      • 7.4.6. Business Performance

      • 7.4.7. Key Strategic Moves and Developments

    • 7.5. Pfizer Inc.

      • 7.5.1. Company Overview

      • 7.5.2. Key Executives

      • 7.5.3. Company Snapshot

      • 7.5.4. Operating Business Segments

      • 7.5.5. Product Portfolio

      • 7.5.6. Business Performance

      • 7.5.7. Key Strategic Moves and Developments

    • 7.6. Sanofi Avantis

      • 7.6.1. Company Overview

      • 7.6.2. Key Executives

      • 7.6.3. Company Snapshot

      • 7.6.4. Operating Business Segments

      • 7.6.5. Product Portfolio

      • 7.6.6. Business Performance

      • 7.6.7. Key Strategic Moves and Developments

    • 7.7. Julphar

      • 7.7.1. Company Overview

      • 7.7.2. Key Executives

      • 7.7.3. Company Snapshot

      • 7.7.4. Operating Business Segments

      • 7.7.5. Product Portfolio

      • 7.7.6. Business Performance

      • 7.7.7. Key Strategic Moves and Developments

    • 7.8. Exir

      • 7.8.1. Company Overview

      • 7.8.2. Key Executives

      • 7.8.3. Company Snapshot

      • 7.8.4. Operating Business Segments

      • 7.8.5. Product Portfolio

      • 7.8.6. Business Performance

      • 7.8.7. Key Strategic Moves and Developments

    • 7.9. SEDICO

      • 7.9.1. Company Overview

      • 7.9.2. Key Executives

      • 7.9.3. Company Snapshot

      • 7.9.4. Operating Business Segments

      • 7.9.5. Product Portfolio

      • 7.9.6. Business Performance

      • 7.9.7. Key Strategic Moves and Developments

    • 7.10. Wockhardt

      • 7.10.1. Company Overview

      • 7.10.2. Key Executives

      • 7.10.3. Company Snapshot

      • 7.10.4. Operating Business Segments

      • 7.10.5. Product Portfolio

      • 7.10.6. Business Performance

      • 7.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL LONG-ACTING INSULIN MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL LONG-ACTING INSULIN MARKET FOR RADITIONAL HUMAN INSULIN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL LONG-ACTING INSULIN MARKET FOR BASAL OR LONG-ACTING INSULIN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL LONG-ACTING INSULIN MARKET FOR BOLUS OR FAST-ACTING INSULIN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL LONG-ACTING INSULIN MARKET FOR  INSULIN COMBINATIONS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL LONG-ACTING INSULIN MARKET FOR BIOSIMILAR INSULIN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL LONG-ACTING INSULIN MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. NORTH AMERICA LONG-ACTING INSULIN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. NORTH AMERICA LONG-ACTING INSULIN, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 10. U.S. LONG-ACTING INSULIN, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 11. CANADA LONG-ACTING INSULIN, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 12. MEXICO LONG-ACTING INSULIN, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 13. EUROPE LONG-ACTING INSULIN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. EUROPE LONG-ACTING INSULIN, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 15. FRANCE LONG-ACTING INSULIN, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 16. GERMANY LONG-ACTING INSULIN, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 17. ITALY LONG-ACTING INSULIN, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 18. SPAIN LONG-ACTING INSULIN, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 19. UK LONG-ACTING INSULIN, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 20. RUSSIA LONG-ACTING INSULIN, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 21. REST OF EUROPE LONG-ACTING INSULIN, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 22. ASIA-PACIFIC LONG-ACTING INSULIN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 23. ASIA-PACIFIC LONG-ACTING INSULIN, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 24. CHINA LONG-ACTING INSULIN, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 25. JAPAN LONG-ACTING INSULIN, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 26. INDIA LONG-ACTING INSULIN, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 27. SOUTH KOREA LONG-ACTING INSULIN, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 28. AUSTRALIA LONG-ACTING INSULIN, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 29. THAILAND LONG-ACTING INSULIN, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 30. MALAYSIA LONG-ACTING INSULIN, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 31. INDONESIA LONG-ACTING INSULIN, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 32. REST OF ASIA PACIFIC LONG-ACTING INSULIN, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 33. LAMEA LONG-ACTING INSULIN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 34. LAMEA LONG-ACTING INSULIN, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 35. BRAZIL LONG-ACTING INSULIN, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 36. SOUTH AFRICA LONG-ACTING INSULIN, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 37. SAUDI ARABIA LONG-ACTING INSULIN, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 38. UAE LONG-ACTING INSULIN, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 39. ARGENTINA LONG-ACTING INSULIN, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 40. REST OF LAMEA LONG-ACTING INSULIN, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 41. NOVO NORDISK: KEY EXECUTIVES
  • TABLE 42. NOVO NORDISK: COMPANY SNAPSHOT
  • TABLE 43. NOVO NORDISK: OPERATING SEGMENTS
  • TABLE 44. NOVO NORDISK: PRODUCT PORTFOLIO
  • TABLE 45. NOVO NORDISK: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 46. ELI LILLY: KEY EXECUTIVES
  • TABLE 47. ELI LILLY: COMPANY SNAPSHOT
  • TABLE 48. ELI LILLY: OPERATING SEGMENTS
  • TABLE 49. ELI LILLY: PRODUCT PORTFOLIO
  • TABLE 50. ELI LILLY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 51. BOEHRINGER INGELHEIM: KEY EXECUTIVES
  • TABLE 52. BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
  • TABLE 53. BOEHRINGER INGELHEIM: OPERATING SEGMENTS
  • TABLE 54. BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO
  • TABLE 55. BOEHRINGER INGELHEIM: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 56. BIOCON LIMITED: KEY EXECUTIVES
  • TABLE 57. BIOCON LIMITED: COMPANY SNAPSHOT
  • TABLE 58. BIOCON LIMITED: OPERATING SEGMENTS
  • TABLE 59. BIOCON LIMITED: PRODUCT PORTFOLIO
  • TABLE 60. BIOCON LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 61. PFIZER INC.: KEY EXECUTIVES
  • TABLE 62. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 63. PFIZER INC.: OPERATING SEGMENTS
  • TABLE 64. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 65. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 66. SANOFI AVANTIS: KEY EXECUTIVES
  • TABLE 67. SANOFI AVANTIS: COMPANY SNAPSHOT
  • TABLE 68. SANOFI AVANTIS: OPERATING SEGMENTS
  • TABLE 69. SANOFI AVANTIS: PRODUCT PORTFOLIO
  • TABLE 70. SANOFI AVANTIS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 71. JULPHAR: KEY EXECUTIVES
  • TABLE 72. JULPHAR: COMPANY SNAPSHOT
  • TABLE 73. JULPHAR: OPERATING SEGMENTS
  • TABLE 74. JULPHAR: PRODUCT PORTFOLIO
  • TABLE 75. JULPHAR: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 76. EXIR: KEY EXECUTIVES
  • TABLE 77. EXIR: COMPANY SNAPSHOT
  • TABLE 78. EXIR: OPERATING SEGMENTS
  • TABLE 79. EXIR: PRODUCT PORTFOLIO
  • TABLE 80. EXIR: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 81. SEDICO: KEY EXECUTIVES
  • TABLE 82. SEDICO: COMPANY SNAPSHOT
  • TABLE 83. SEDICO: OPERATING SEGMENTS
  • TABLE 84. SEDICO: PRODUCT PORTFOLIO
  • TABLE 85. SEDICO: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 86. WOCKHARDT: KEY EXECUTIVES
  • TABLE 87. WOCKHARDT: COMPANY SNAPSHOT
  • TABLE 88. WOCKHARDT: OPERATING SEGMENTS
  • TABLE 89. WOCKHARDT: PRODUCT PORTFOLIO
  • TABLE 90. WOCKHARDT: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL LONG-ACTING INSULIN MARKET SEGMENTATION
  • FIGURE 2. GLOBAL LONG-ACTING INSULIN MARKET
  • FIGURE 3. SEGMENTATION LONG-ACTING INSULIN MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN LONG-ACTING INSULIN MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALLONG-ACTING INSULIN MARKET
  • FIGURE 11. LONG-ACTING INSULIN MARKET SEGMENTATION, BY BY PRODUCT TYPE
  • FIGURE 12. LONG-ACTING INSULIN MARKET FOR RADITIONAL HUMAN INSULIN, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. LONG-ACTING INSULIN MARKET FOR BASAL OR LONG-ACTING INSULIN, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. LONG-ACTING INSULIN MARKET FOR BOLUS OR FAST-ACTING INSULIN, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. LONG-ACTING INSULIN MARKET FOR  INSULIN COMBINATIONS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. LONG-ACTING INSULIN MARKET FOR BIOSIMILAR INSULIN, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 18. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 19. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 20. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 21. COMPETITIVE DASHBOARD
  • FIGURE 22. COMPETITIVE HEATMAP: LONG-ACTING INSULIN MARKET
  • FIGURE 23. Top player positioning, 2022
  • FIGURE 24. NOVO NORDISK: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 25. NOVO NORDISK: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 26. NOVO NORDISK: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 27. ELI LILLY: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 28. ELI LILLY: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 29. ELI LILLY: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 30. BOEHRINGER INGELHEIM: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 31. BOEHRINGER INGELHEIM: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 32. BOEHRINGER INGELHEIM: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 33. BIOCON LIMITED: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 34. BIOCON LIMITED: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 35. BIOCON LIMITED: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 36. PFIZER INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 37. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 38. PFIZER INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 39. SANOFI AVANTIS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 40. SANOFI AVANTIS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 41. SANOFI AVANTIS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 42. JULPHAR: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 43. JULPHAR: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 44. JULPHAR: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 45. EXIR: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 46. EXIR: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 47. EXIR: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 48. SEDICO: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 49. SEDICO: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 50. SEDICO: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 51. WOCKHARDT: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 52. WOCKHARDT: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 53. WOCKHARDT: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now
RELATED TAGS

Purchase Full Report of
Long-acting Insulin Market

Start reading.
This Report and over 67,069+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers